- Home
- ATLCP vs CADL Comparison
ATLCP vs CADL Comparison
Compare ATLCP & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ATLCP
Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Current Price
Company Overview
Basic Information| Metric | ATLCP | CADL |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | 417 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATLCP | CADL |
|---|---|---|
| Price | $24.00 | $5.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | N/A | ★ 1.0M |
| Earning Date | N/A | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $4.25 |
| 52 Week High | N/A | $13.68 |
Technical Indicators
Market Signals| Indicator | ATLCP | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 60.36 |
| Support Level | $23.85 | $5.48 |
| Resistance Level | $24.20 | $5.98 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 60.00 | 63.13 |
Price Performance
Historical ComparisonAbout ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.